Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.41 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380243 | 0.87 | ALDH1A1 (0.41) | DRD4DRD2DRD3MCHR1ALDH1A1 | |
| SCHEMBL4841026 | 0.82 | CNR2 (0.39) | TP53 | |
| SCHEMBL5669316 | 0.82 | MCHR1 (0.39) | DRD4DRD2DRD3MCHR1KDM4E | |
| SCHEMBL4844584 | 0.81 | CNR1 (0.36) | CYP3A4TP53 | |
| SCHEMBL4833058 | 0.81 | CNR1 (0.38) | HSD17B10MAPK1HPGD | |
| SCHEMBL8444084 | 0.80 | CNR2 (0.35) | ALDH1A1TP53 | |
| SCHEMBL4840644 | 0.77 | CNR1 (0.40) | ALDH1A1KDM4EMAPK1HPGDMEN1 | |
| SCHEMBL4840849 | 0.75 | CNR1 (0.40) | ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL5607652 | 0.75 | CNR1 (0.40) | ALDH1A1MEN1KMT2ATP53HTT | |
| SCHEMBL4840591 | 0.74 | CRHR1 (0.39) | MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007502808-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | claimed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| WO-2004069837-A1 | PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | DRD4 1341/4885DRD2 609/4885DRD3 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.